Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KCNJ6 | P48051 | 8/20 | 0.33 |
| ▸ | KCNJ3 | P48549 | 8/20 | 0.33 |
| ▸ | CRACR2A | Q9BSW2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMO | O15229 | 1/20 | 0.33 |
| ▸ | KCNJ5 | P48544 | 4/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4138174 | 0.84 | NPC1 (0.40) | SMN1; SMN2NPC1LMNATP53PKM | |
| SCHEMBL5597486 | 0.78 | SRC (0.48) | SMN1; SMN2NPC1LMNATP53PKM | |
| SCHEMBL173999 | 0.77 | KDM4E (0.41) | SMN1; SMN2NPC1LMNATP53PKM | |
| SCHEMBL27409551 | 0.75 | GAA (0.42) | SMN1; SMN2NPC1LMNATP53PKM | |
| SCHEMBL21824339 | 0.71 | HRH4 (0.46) | SMN1; SMN2NPC1LMNATP53PKM | |
| SCHEMBL6783179 | 0.71 | KDM4E (0.40) | SMN1; SMN2NPC1LMNATP53PKM | |
| SCHEMBL27157379 | 0.71 | HCAR2 (0.32) | HCAR2CRACR2AHDAC3 | |
| SCHEMBL21824356 | 0.70 | HRH4 (0.44) | SMN1; SMN2NPC1LMNATP53PKM | |
| SCHEMBL21824376 | 0.70 | ALDH1A1 (0.44) | SMN1; SMN2LMNATP53PKMPOLB | |
| SCHEMBL574082 | 0.69 | NPC1 (0.45) | SMN1; SMN2NPC1LMNATP53PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3424924-B1 | UREA COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | ANCUREALL PHARMACEUTICAL SHANGHAI CO LTD (CN) | 2023-05-24 | — | — | EP | claimed |
| US-10647680-B2 | Urea compound, preparation method therefor and medical use thereof | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2020-05-12 | — | — | US | claimed |
| US-20190047964-A1 | UREA COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2019-02-14 | — | — | US | claimed |
| EP-3424924-A1 | UREA COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Ancureall Pharmaceutical (Shanghai) Co., Ltd. (CN) | 2019-01-09 | — | — | EP | claimed |
| CN-109071523-A | Urea compound, preparation method and medical application thereof | 恩瑞生物医药科技（上海）有限公司 | 2018-12-21 | — | — | CN | claimed |
| CN-107176951-A | A kind of carbamide compounds, its preparation method and its medical usage | 恩瑞生物医药科技（上海）有限公司 | 2017-09-19 | — | — | CN | claimed |
| WO-2023203174-A1 | HETEROCYCLIC CULLIN RING UBIQUITIN LIGASE COMPOUNDS AND USES THEREOF | PROXYGEN GMBH (AT) | 2023-10-26 | — | — | WO | disclosed |
| US-20230279012-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| EP-3424924-B1 | UREA COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | ANCUREALL PHARMACEUTICAL SHANGHAI CO LTD (CN) | 2023-05-24 | — | — | EP | disclosed |
| EP-4050012-A1 | PYRIDONE BORONATES FOR THE PREPARATION OF INHIBITORS OF BTK ACTIVITY | F. Hoffmann-La Roche AG (CH) | 2022-08-31 | — | — | EP | disclosed |
| EP-4019508-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | F. Hoffmann-La Roche AG (CH) | 2022-06-29 | — | — | EP | disclosed |
| CN-109071523-B | Urea compound, preparation method and medical application thereof | 恩瑞生物医药科技（上海）有限公司 | 2022-05-31 | — | — | CN | disclosed |
| EP-3521288-B1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | HOFFMANN LA ROCHE (CH) | 2021-09-08 | — | — | EP | disclosed |
| WO-2012031004-A1 | PYRIDINONES/PYRAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| US-20120010191-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| WO-2011140488-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GILEAD CONNECTICUT, INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| CN-101155800-A | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | ASTRAZENECA AB (SE) | 2008-04-02 | — | — | CN | disclosed |
| CN-101119996-A | chemical compound | ASTRAZENECA AB (SE) | 2008-02-06 | — | — | CN | disclosed |
| EP-1345909-A1 | PHENYLACETAMIDO-PYRAZOLE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS | Pharmacia Italia S.p.A. (IT) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002048114-A1 | PHENYLACETAMIDO- PYRAZOLE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA ITALIA S.P.A. (IT) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190047964-A1 | UREA COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | FLT3, WEE1, SLC14A1 | SMN1; SMN2 4767/4885NPC1 2390/4885LMNA 3939/4885 |
| US-10647680-B2 | Urea compound, preparation method therefor and medical use thereof | FLT3, WEE1, SLC14A1 | SMN1; SMN2 4767/4885NPC1 2390/4885LMNA 3939/4885 |
| US-20120010191-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | PDXK, BTK, LCK | SMN1; SMN2 2770/4885NPC1 4832/4885LMNA 2383/4885 |
| US-20230279012-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | PDXK, BTK, TYK2 | SMN1; SMN2 3549/4885NPC1 4847/4885LMNA 2651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.